Radiopharm Theranostics Limited is an Australia-based clinical-stage company developing a platform of radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. It has a pipeline of differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer, in pre-clinical and clinical stages of development from some of the universities and institutes around the world. The clinical program includes one Phase II and two Phase I trials in a variety of solid tumor cancers including lung, pancreas and brain. Its technologies include Nano-mAbs, Pivalate, AVB6 Integrin, PSA-mAb, DUNP19 and PTPu. Nano-mAbs is a radiopharmaceutical platform made using genetic engineered camelid derived single domain antibodies (sdAb) labelled with a radioisotope of therapeutic radiation. Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate that utilizes the early steps of fatty acid oxidation.

• Revenue in AUD (TTM)0.00
• Net income in AUD-46.82m
• Incorporated2021
• Employees--

• Location
  Radiopharm Theranostics Ltd62 Lygon Street, Carlton, Level 3MELBOURNE 3053AustraliaAUS
• Phone+61 39824-5254
• Websitehttps://radiopharmtheranostics.com/